{"name":"CRISPR Therapeutics AG","slug":"crispr-therapeutics-ag","ticker":"","exchange":"","domain":"","description":"CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CTX112","genericName":"CTX112","slug":"ctx112","indication":"Other","status":"phase_1"},{"name":"CTX131","genericName":"CTX131","slug":"ctx131","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CTX112","genericName":"CTX112","slug":"ctx112","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CTX131","genericName":"CTX131","slug":"ctx131","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBCcTNHbThhaEJuTmlSaVZHQWRVYmhMUEdfWUpkRmowSkkybzhOV25HUjlfX1NtOVprODhma0NfdWgtb0tVYXRLNlFWS3plUDN4LUE?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance Singapore","summary":"CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance Singapore","headline":"CRISPR Therapeutics AG (CRSP) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNVRiQmpzbVVnM2RUR2tRZHhfLUlSaDlDbWhIRHdfWjg5YUc2dGM4Wmh2YVJoMnFBOTIyaUdVc1I3WWp0NjZ1eDlPUjBMUUNaZWVnajRqam5OekNKNl9lRFZEbFMwd05vOFFOU3A2c3cxZm14U2ZnQWRYTEY3RVU2WDZxaGhHeDM1UFdN?oc=5","date":"2026-03-10","type":"pipeline","source":"Finviz","summary":"Here is Why CRISPR Therapeutics (CRSP) Appears so Good - Finviz","headline":"Here is Why CRISPR Therapeutics (CRSP) Appears so Good","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUWwwQkpPWXNiRUM2SjM3emo0aWZmUlBhMl9NcFd2V2pnT3VfLXhHRXd1cEJKS3h5Y3NmcFBCWE1CMS03bjA3ckZRS3NrMV9Wb1NDQ0RkRGFJYmI5V1hIMlNmb292bXI5WGwxSFUtTXNhQ2ZJQWtkVzZ2Z0hLbE1kbUJYMVVTeHk4Sk53c3V6N0RDdGFoZURNWDFZeTdGUXQzV3NlV2JzMzU5TVU?oc=5","date":"2026-03-09","type":"deal","source":"Seeking Alpha","summary":"Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP) - Seeking Alpha","headline":"Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1vN0ZSV0Y5Nnd2a1NBZVZSeFZNZU1Uakstamd3eDhnZjVkRG84cWlPRGphRm5UTnYyNWd0cDhmTVJZMHNnTDNSQVduRHFqeVF0WnBIdDNJN1JwMDVOaWRyWlBuRkpyOFd5Tl84M2VIYlNvZHlfSGFLRQ?oc=5","date":"2026-02-27","type":"deal","source":"U.S. News Money","summary":"7 Top Gene-Editing Stocks to Buy - U.S. News Money","headline":"7 Top Gene-Editing Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOSmJXRm9xaDN5blJvLXZ0ZUt0RGxlVUNxUVlOOXNCS1doYmRibjRkVWlQY1FvalFoUGVEYXRyb0Z0bElOcFZOOUxaLUE0RkdpdGQ3VUo3MjZWNHpHbUI0a2hDQTk5Um03bzI0WkhXeXJXTFhTWmR5Z1hleUFjUklwVzVoT2RSWGw1VU1KNmVzWlg3bDd3VC1teFJqZWJKRnpyMnVaUE8tSjJGQ1ZSc1VqbnpKRFhjN2w4ckVNWDNNdEdtbGd1VldVUGhsX09hQnRUcHh5NHdPSzR2X3diVTUzTkpPc1MtcFA1Z3BNNWpTWWtoSnY4cjRZc0kyWmlJdzdqZlBuZGlGWVBieDQ0Nm1aT05ZNk5RY2tGSE1BQWw5WmVTNENyclgzVkZhYmRxTXl2eFBSVUxB?oc=5","date":"2026-02-18","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQcW1UdV8wbGtwTTlScHRfUk1EYW1GVFNiWDdjSjhXYlBsc1hlOEpZMUg2LXN0aDN5dmpjbFRyTDJVWmMzWGExdmw5WDhPVWJOQUluSlBJTkFPOUl2TEM0ak9qd3F3Znd2ZE15XzVBNWMzSkJuYjczeUJhR2NUaVd6NE9XWnFhcU1heGszaGJNT0I1MW5YcmJ6cWZCRUh0WTZneGJaUHZraTQxaTg5ODVsNDZrVWVxQlpBOURoY1ZXWmYyRVZQUFNNSGZRWFBtal9tM0FWYmlKYnVjQUViSktMaF91X0t6YzVtS3hoRERJVXl2TnNWOEFWQkZDQWcxZjg1SGlRTmQzMjNmd3VM?oc=5","date":"2026-02-12","type":"earnings","source":"GlobeNewswire","summary":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire","headline":"CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1LVzQxbTd5SlM0VzVDWWU4dGxVUUk1SGFkc3RncGc4OFB5dTJfN1VQS3pzVGVWV3RtZjJ5NHBRc3FqLVBBTmMzS2pKRkxiQXhEeEhPWGs2ejVmTlRQUkZiRDhaTmg1TVNpRmc?oc=5","date":"2026-02-05","type":"deal","source":"morningstar.com","summary":"The Best Biotech Stocks to Buy - morningstar.com","headline":"The Best Biotech Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOQkQ0UGJONndVQjYwdmZvTThrUmJweE5oMG5oRklvQ2ltalRsX0xsY25McHVwb19HU2lPXzk3U0JGZ0RJN2ZFOHZoMEhERjMzckRETzNISTFJTVdqMHdGQ3lNLVhQTVpYb0tfV3hwVjRVTlBlM1M5SWlkV1U3Ym1xY1QyaWpSQQ?oc=5","date":"2025-12-12","type":"deal","source":"Finviz","summary":"2 Healthcare Stocks to Buy Ahead of the New Year - Finviz","headline":"2 Healthcare Stocks to Buy Ahead of the New Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOWThkMTFHZl8tQWdvbG5ieUpBMHlYdVI1RVhSbmFFNmVTMlBxeWkxQ1VWVkRnR0ZZV2NQYnJIN29oTEU4ck1ubHRJbHpyT0c4UVF1UkV4S0s0UmV2Y183LWJNS2twNHNDY3RYYXBDUGJES0Vwb0s2UHRxSXlDV0ZDcXpXOWJNN0pyc0JudDF2Z0ZIT3RhMHNVOC1pcENwODFBdUozY1lqbzJ2Q0tpZHpfZVpvcTFHa3BfSGZPdHR6bUh3Z2xpSUpFWTgwQXhKcWFJVzdKZlROSExyZUNz?oc=5","date":"2025-12-06","type":"pipeline","source":"Reuters","summary":"Vertex's gene therapy shows promise in younger children with blood disorders - Reuters","headline":"Vertex's gene therapy shows promise in younger children with blood disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZV9NVEJhVHNGbDJ3S1NCQ3JielFUYklaaGFwS214ZTQ0SV8xdGFqOWd4emVIRk9Gc3NNUjFOYk5LRjgxZkItcWdoVU5OaGdtV1VUcjdJYWJQSTJZY0Y2UUZqbkdtajJNSlhkRXVKVWwyMHNVdE9MMHdxM3l2Zko1ZlcycFN2U0xXVFpjWUs4NHgzSXdqMW9sMmUwOEI2LU9ndzhvN2QtbXBMckxudlZkQ2hSb1RkSUZjbk1oRDdn?oc=5","date":"2025-09-17","type":"earnings","source":"Seeking Alpha","summary":"Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track (CRSP) - Seeking Alpha","headline":"Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track (CRSP)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNM2d1RktIUGFZMVQwazZySGo4VkFYc2ZRYmxxekJtUmRQblNvTndFWHRaYkN6bVE1X2pkRndGZUI1TThzb0M2OUJKc2s4bkgyZWc5U2JMeTFXS3RUNk1iNVU2bklFdnU3YWVtQzJubU5pVjdoVk1PbktGbHpJY1ZKZjhzbTVkcTl1OWhYRXZfRjFNT2MzQ2JaazhiM2VGZzJodkw0Tm1mc1pWQWhidmFrMUQ4Nk9Ya1VjeGhubGNBcU1oNDJmZXVQOWdyX2s4aW8wXzRWTERhWkRtTzlnRHV4d19keDQxZVh6cjhRVUFvZHg5RjN1ay1CTHZLdV9nOXFKbWVpd3hRWTBQN0RaZUJQMFRn?oc=5","date":"2025-05-19","type":"deal","source":"GlobeNewswire","summary":"CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies - GlobeNewswire","headline":"CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE0wUTMyS04zVDhrcUpDaGZRNXFMNE9lYUtoYk5GUi1RbXFLUmdReXZZT2dpS2FfWHZhYVYtRzJ1V01Yd3ZEXzdqVVRCUWJxcjBPaXFCUkhaRWliR2pSaEZoeEtIR1BoUQ?oc=5","date":"2024-09-09","type":"pipeline","source":"Fierce Pharma","summary":"CRISPR Therapeutics - Fierce Pharma","headline":"CRISPR Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}